High-performance liquid chromatography-UV diode array, inductively coupled plasma mass spectrometry (ICMPS) and orthogonal acceleration time-of-flight mass spectrometry (oa-TOFMS) applied to the simultaneous detection and identification of metabolites of 4-bromoaniline in rat urine F. R. Abou-ShakraA. B. SageI. D. Wilson OriginalPaper Pages: S9 - S13
Hyphenation of CE to ICP-MS and to sheathless electrospray-MS for high sensitivity and selectivity in bioanalysis S. H. HansenL. BendahlO. Farver OriginalPaper Pages: S15 - S19
High-throughput analysis of biological samples by direct coupling of solid-phase (micro-)extraction and mass spectrometry M. W. J. van HoutC. M. HoflandG. J. de Jong OriginalPaper Pages: S23 - S24
Video microscopy and confocal laser scan microscopy to study the mechanisms of cytotoxicity in individual living cells. Application and new developments J. F. NagelkerkeH. J. G. M. de Bont OriginalPaper Pages: S25 - S29
Serial sampling in the mouse in support of pharmacokinetic studies with turbulent flow chromatography and tandem mass spectrometry J. M. LongC. A. JamesS. Rolando OriginalPaper Pages: S31 - S34
Comparison of three methods for pharmacokinetic screening in rats using LC-MS-MS S. BriemE. EklundJ. Brunvoll OriginalPaper Pages: S35 - S39
Fast turnaround bioanalysis in discovery and early clinical development C. A. JamesM. BredaK. Munesada OriginalPaper Pages: S41 - S43
The application of microbore liquid chromatography/mass spectrometry to the routine analysis of a drug in plasma S. LüdtkeH. SwitekJ. Schmid OriginalPaper Pages: S45 - S51
Advances in MS-based approaches for drug and metabolism studies J. Castro-PerezJ. HoyesS. Preece OriginalPaper Pages: S59 - S63
Towards molecular-imprint based SPE of local anaesthetics L. I. AnderssonM. Abdel-RehimS. Nilsson OriginalPaper Pages: S65 - S69
Some experiences with a mass spectrometry data system validation D. BrowneT. ThompsonR. D. McDowall OriginalPaper Pages: S75 - S78
Where do you draw the line? Points to consider when implementing the FDA method validation guidance on quantifying chromatographic peaks H. M. HillJ. SmeragliaG. T. Smith OriginalPaper Pages: S79 - S81
Regulatory aspects of bioanalysis in preclinical and clinical studies H. M. Hill OriginalPaper Pages: S83 - S84
The impact of 21 CFR 11 (Electronic records and electronic signatures final rule) on bioanalysis R. D. McDowall OriginalPaper Pages: S85 - S90
Validation issues arising from the new FDA guidance for industry on bioanalytical method validation R. R. BrodieH. M. Hill OriginalPaper Pages: S91 - S94
Addendum(summary by H. M. Hill): Discussion at forum of this and preceding presentations Erratum Pages: S94 - S94
Matrix effects and selectivity issues in LC-MS-MS J. SmeragliaS. F. BaldreyD. Watson OriginalPaper Pages: S95 - S99
Ligand binding assays and anti-drug antibodies, analytical approaches and validation issues P. D. Overton OriginalPaper Pages: S101 - S106
Evolving bioanalytical methods for the cardiovascular drug bosentan D. DellB. LauseckerJ. Dingemanse OriginalPaper Pages: S115 - S119
Application of LC-SIM-MS. Determination of a neurokinin receptor antagonist in human plasma by column-switching HPLC and automated sample processing P. HeizmannR. HérisséR. Gössl OriginalPaper Pages: S121 - S125
A generic approach for the HPLC separation of quinolone antibiotics G. JohnsonS. WestwoodR. Houghton OriginalPaper Pages: S127 - S131
Determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by liquid chromatography-tandem mass spectrometry R. GreenR. HoughtonC. Gregory OriginalPaper Pages: S133 - S136
Development of high performance liquid chromatography tandem mass spectrometric methods for the determination of a novel ascomycin-based immunoregulant in human whole blood and plasma: A case of potential analyte loss during sample collection I. FuE. J. WoolfB. K. Matuszewski OriginalPaper Pages: S137 - S144
Determination of cetirizine in human plasma by liquid chromatography-tandem mass spectrometry H. EriksenR. HoughtonJ. Scarth OriginalPaper Pages: S145 - S149
Analysis of a [14C]-labelled platinum anticancer compound in dosing formulations and urine using a combination of HPLC-ICPMS and flow scintillation counting C. J. SmithI. D. WilsonM. Malone OriginalPaper Pages: S151 - S155
Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-Ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography J. CummingsB. T. EthellD. I. Jodrell OriginalPaper Pages: S157 - S163
Special problems associated with the bioanalysis of anti-cancer drugs C. A. JamesM. BredaK. Munesada OriginalPaper Pages: S165 - S170
The impact of stability and solubility of photodynamic therapies on method development G. T. SmithT. YangG. R. Morris OriginalPaper Pages: S171 - S175
Bioanalysis of temoporfin, a new pharmacodynamic therapy agent R. WhelptonA. T. Michael-TitusA. Fox OriginalPaper Pages: S177 - S181
Improved methods for the analysis of paraquat in biological fluids D. K. BlakeR. T. GallagherB. H. Woollen OriginalPaper Pages: S183 - S185
Comparison of LC-UV and LC-MS-MS for the determination of taxol S. F. BaldreyR. R. BrodieS. T. Brookes OriginalPaper Pages: S187 - S192
Measurement of plasma tyrosine by HPLC-UV or LC-MS-MS for assessing chemically induced tyrosinaemia P. C. HolmeK. A. Woods OriginalPaper Pages: S193 - S194
Development of a sensitive assay for the determination of mevalonic acid in urine and its application to clinical studies with rosuvastatin B. H. WoollenP. C. HolmeP. D. Martin OriginalPaper Pages: S195 - S196
